Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
12 mai 2023 16h05 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
12 mai 2023 08h30 HE
|
Avenue Therapeutics
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
11 mai 2023 16h03 HE
|
Mustang Bio, Inc.
Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May ...
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
27 avr. 2023 08h30 HE
|
Avenue Therapeutics
MIAMI, April 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
17 avr. 2023 16h01 HE
|
Avenue Therapeutics
MIAMI, April 17, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
30 mars 2023 20h00 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced...
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
30 mars 2023 16h10 HE
|
Fortress Biotech, Inc.
Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application...
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
30 mars 2023 16h01 HE
|
Avenue Therapeutics
MIAMI, March 30, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
29 mars 2023 16h15 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
29 mars 2023 16h01 HE
|
Journey Medical Corporation
Generated record total revenues of $73.7 million for the full year 2022 Completed enrollment in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea; topline data...